Lumiracoxib

Research use only, not for human use.

Lumiracoxib is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1. Phase 4.

Lumiracoxib, also known as CGS 35189 and COX 189, is a COX-2 selective inhibitor non-steroidal anti-inflammatory drug, manufactured by Novartis and still sold in few countries, including Mexico, Ecuador and the Dominican Republic, under the trade name Prexige. Since its original approval, lumiracoxib has been withdrawn from the market in several countries, mostly due to its potential for causing liver failure (sometimes requiring liver transplantation). It has never been approved for use in the United States.

CGS-35189;CGS35189; COX 189; Lumiracoxib

Others

Other Targets

COX-1; COX-2

Others-Field

——

220991-20-8

293.72

C15H13ClFNO2

98%

——

Clc2cccc(F)c2Nc1ccc(C)cc1CC(=O)O

2-(2-((2-chloro-6-fluorophenyl)amino)-5-methylphenyl)acetic acid

(-20℃)

With Ice Pack

≥ 2 years